Nanosonics (ASX:NAN): FY26 trophon Results and the Next Stage for CORIS

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Nanosonics (ASX:NAN): FY26 trophon Results and the Next Stage for CORIS

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Nanosonics (ASX:NAN) generated AUD 203.9 million FY26 revenue, up 3%.
Global trophon placements increased 9% to 4,230 units.
FY26 EBIT was AUD 16.0 million, down 10% on reported figures.
CORIS commercial launches are planned in selected markets during FY27.

Nanosonics Limited (ASX:NAN) develops infection-prevention technologies for healthcare facilities, including automated ultrasound-probe reprocessing and an endoscope-cleaning platform. On 12 November 2026, NAN shares were trading at AUD 2.845, up 2.34% for the session. Its August FY2026 results detailed further trophon installations, a currency-affected Earnings outcome and preparations to expand commercial availability of the CORIS system during FY2027.

trophon Devices and Endoscope Reprocessing

Nanosonics (ASX:NAN) operates internationally, with trophon technology used for high-level disinfection of compatible ultrasound probes. The Business includes equipment sales, consumables, service and related products. It also develops the CORIS system for endoscope reprocessing, which is at a different commercial stage. The distinction matters: trophon already generates substantial recurring revenue, while CORIS requires Investment and additional customer uptake as the company moves from controlled market release toward broader commercialisation. Neither device-placement figures nor regulatory permissions alone measure the eventual profitability of a new product.

FY26 Unit Placements and Installed Base

During the year ended 30 June 2026, Nanosonics (ASX:NAN) recorded 4,230 trophon unit placements, up 9% from the previous corresponding period. Its cumulative installed base increased 6% to 39,230 devices. North American upgrades reached 1,980 units, 32% higher year on year, and total placements in that market were 3,880. The newer trophon3 product and trophon2 Plus software upgrades were introduced during the year. As more customers upgrade devices, sales mix and pricing can change alongside the continuing consumables and servicing activity associated with the installed fleet.

Revenue, EBIT and Cash Position

FY26 Revenue reached AUD 203.9 million, up 3% on a reported basis. Nanosonics (ASX:NAN) said revenue would have been AUD 211.5 million at constant currency, representing 6% growth. Reported earnings before interest and tax declined 10% to AUD 16.0 million, whereas constant-currency EBIT was AUD 21.6 million, up 21%. The business reported AUD 149.2 million in Recurring Revenue and AUD 54.7 million in Capital revenue. Cash and equivalents were AUD 155.2 million at year-end, with no debt, after the company completed a AUD 20 million share buyback.

CORIS Progress and FY27 Guidance

Nanosonics (ASX:NAN) reported controlled market releases of CORIS and regulatory milestones across several markets. It planned a commercial launch in the United Kingdom, Ireland and Australia during the first half of FY27, with the US launch to follow. The company's FY27 constant-currency revenue guidance was AUD 220 million to AUD 228 million, alongside an expected gross Margin of 74%–76% and operating expenses of AUD 156 million to AUD 163 million. Management expected CORIS to contribute initial revenue in the low single-digit millions, rather than become a mature earnings contributor immediately.

Cost and Implementation Considerations

Nanosonics (ASX:NAN) indicated that CORIS commercialisation would require higher spending on market development, customer engagement and rollout. Its outlook also referred to Tariff and freight influences on gross margin. Revenue converted at actual exchange rates may differ from constant-currency guidance because of currency movements. Clinical adoption, operational reliability, compliance obligations and the pace of endoscope indications covered by regulatory clearance remain relevant milestones. FY27 outcomes should be assessed against the company's reporting rather than assuming that controlled-market experience automatically translates into rapid commercial sales. The company also indicated a new on-market share buyback of up to AUD 40 million during FY27, distinct from its product launch spending.

Key Insights

Nanosonics (ASX:NAN) ended FY26 with higher trophon placements and revenue, though reported EBIT declined. Its Balance Sheet and existing equipment base provide context for planned CORIS spending. The next reporting periods will show how trophon device upgrades, recurring revenue, foreign-exchange effects and the phased CORIS launch combine in the company's actual financial results.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.